Participating in a Trial
Physicians at leading research institutions who specialize in the treatment of PH are conducting the PHYOXTM clinical trials.
If you or a loved one has been diagnosed with PH and would like to participate in a clinical trial, please submit your information through the forms on the appropriate study pages. Please note, depending on a person’s eligibility to participate in the clinical trial, travel expenses to a clinical trial site will be covered by Dicerna.
Studies Closed to Recruitment:
for participants with PH1 or PH2 (NCT03847909)
Dicerna’s pivotal trial was designed to evaluate the efficacy and safety of nedosiran delivered as a once-monthly subcutaneous injection in participants aged six years and older who have PH1 or PH2. Enrollment of 35 participants was completed in December 2020 and included participants across 11 countries, including the U.S., Japan and Europe
for participants who complete PHYOXTM trials (NCT04042402)
Dicerna’s ongoing open-label three-year extension study for participants who have completed another PHYOXTM study (except PHYOX7)
Siblings of participants in this trial may be enrolled directly into PHYOX3, if eligible
Residents of the European Union can use EudraCT, a database of ongoing clinical trials in the EU, to access more information about the PHYOXTM trials.
About Primary Hyperoxaluria
Primary hyperoxaluria (PH) is a family of severe, ultra-rare, genetic liver disorders characterized by the overproduction of oxalate, a natural chemical in the body that is normally eliminated as waste through the kidneys. For more information on PH, click here.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.